Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 2, 2003, Pages 217-222

  Lee, K K C ^a   You, J H S ^a   Ho, J T S ^a   Suen, B Y ^a   Yung, M Y ^a   Lau, W H ^a   Lee, V W Y ^a   Sung, J Y ^b   Chan, F K L ^b  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DICLOFENAC; OMEPRAZOLE;

ADULT; AGED; ARTHRITIS; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COST; FEMALE; HEALTH CARE COST; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; OMEPRAZOLE; PEPTIC ULCER HEMORRHAGE; PYRAZOLES; RISK FACTORS; SULFONAMIDES;

EID: 0041627439     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01680.x     Document Type: Article

References (12)

1. Chan TYK, Critchley JAJH, Lau JTF, et al. The relationship between upper gastrointestinal hemorrhage and drug use: a case control study. Int J Clin Pharmacol Therapeutics 1996; 34(7): 304-8.
2. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal antiinflammatory drug-associated gastropathy: incidence and risk factors model. Am J Med 1991; 91: 213-22.
3. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal antiinflammatory drugs. Lancet 1994; 343: 1075-8.
4. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43: 1905-15.
5. Hong Kong SAR Government website: http://www.info. gov.hk.
6. Woo J, Ho SC, Chan SG, et al. An estimate of chronic disease burden and some economic consequences among the elderly Hong Kong population. J Epidemiol Community Health 1997; 51: 486-9.
7. Chancellor JVM, Hunsche E, de Cruz E, Sarasin FP. Economic evaluation of celecoxib, a new cyclo-oxydencase 2 specific inhibitor, in Switzerland. Pharmacoeconomics 2001; 19(Suppl. 1): 59-75.
8. Bae SC, Corzillius M, Zkuntz KM, Liang MH. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long term treatment of rheumatoid arthritis. Rheumatology 2003; 42: 46-53.
9. National Institute for Clinical Excellence, July 2001, Technology Appraisal no. 27.
10. You JHS, Lee KKC, Chan TYK, et al. Arthritis treatment in Hong Kong - cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. Aliment Pharmacol Ther 2002; 16: 2089-96.
11. Chan FKL, Hung LCT, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104-10.
12. Burke TA, Zabinski RA, Pettitt D, et al. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Pharmacoeconomics 2001; 19(Suppl. 1): 33-47.